Issues: Vax Specific

Anthrax

Hepatitis B

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

● 2009 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

FirstPreviousNextLast

Dr. Halsey's presentation at the National Vaccine Advisory Committee Workshop on Thimerosal and Vaccines held in Bethesda, Maryland on August 11-12, 1999..

Slide 25 of 26
    Slide Notes:

    To maintain public confidence in vaccines, we should put the mercury content in the label. We also need to revise vaccine information statements to include specific information about mercury exposures. These forms are our primary tools for communicating potential risks to recipients of vaccines and parents.

    We also need to provide physicians with more precise guidelines regarding maximum allowable exposures on a given day. Should we have separate specific recommendations for the highest risk populations● This has never been very practical, and I believe we need to have guidelines that are applicable to all of the population, including the most vulnerable.

    Also, vaccines with little or no thimerosal should be preferred for use in infants as has been recommended by the European Union.